Rapid Approvals of New Therapies to Augment the Major Depressive Disorder (MDD) Treatment Market Growth

 

Major Depressive Disorder Treatment

Major depressive disorder, also called clinical depression, is an extremely serious psychiatric disorder characterized by at least 2 weeks of persistent, severe, and unpredictable low mood. Loss of interest in normally pleasurable activities, lowered self-esteem, low energy, aches and pains without a definite cause, and feelings of worthlessness and guilt are typical symptoms.

Diagnosis usually depends on the medical history of the patient and is made according to the Diagnostic and Statistical Manual for Mental Disorders IV-TR, which lists disorders in three categories based on the extent of the symptoms, the signs or symptoms, the time period they last for, the reaction of the patient to normal situations, and the patient's reaction to stress.

Market Dynamics:

Rapid approvals of new therapies from regulatory bodies, such as the United States Food and Drug Administration and the European Commission, are expected to augment the growth of the major depressive disorder (MDD) treatment market. For instance, in February 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has authorized the use of SPRAVATO (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of major depressive disorder (MDD), as acute short term treatment, for the rapid reduction of depressive symptoms.

Moreover, increasing prevalence of MDD, especially in North America, is expected to propel the growth of the major depressive disorder (MDD) treatment market. MDD is one of the most common mental health disorders in the United States. For instance, according to the Anxiety and Depression Association of America (ADAA), MDD affects more than 16.1 million American adults, or about 6.7% of the U.S. population age 18 and older.

Increasing awareness about various depression episodes and the growing geriatric population worldwide is expected to offer lucrative growth opportunities for players in the market.

Competitive Analysis:

Major players operating in the major depressive disorder (MDD) treatment market are Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline, Merck & Co., AstraZeneca Plc., Pfizer, Johnson & Johnson, Lundbeck, Alkermes, Allergan, and Takeda Pharmaceutical Company Limited.

In February 2021, Otsuka and Click Therapeutics announced the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD).

In February 2021, MYND Life Sciences Inc. signed a Collaborative Research Agreement with the University of British Columbia focusing on Major Depressive Disorder (MDD), often referred to as depression.